Global law firm White & Case LLP has advised Mabion S.A. (Mabion) on the issuance and offering of shares to institutional investors in an accelerated bookbuilding process.
Investors took up the entire offered block of shares, constituting almost 20 percent of the company's shares admitted to trading on the Warsaw Stock Exchange (WSE). The offer shares will be listed on the WSE pursuant to an exemption from obligation to publish a prospectus. mBank S.A. acted as Sole Global Coordinator and Sole Bookrunner.
The capital raised will allow Mabion to continue work on its flagship drug MabionCD20, and expand production capacity related to the planned production of a Covid-19 vaccine in cooperation with the American vaccine developer Novavax.
WSE-listed Mabion is a Polish biotechnology company whose primary objective is to develop, manufacture and market biopharmaceutical medicines.
The White & Case team in Warsaw which advised on the transaction was led by partner Marcin Studniarek and included counsel Bartosz Smardzewski and associates Damian Lubocki and Michał Truszczyński.
For more information please speak to your local media contact.